Good news! The medical insurance reimbursement status of dasatinib has been released
Dasatinib (Dasatinib), as a tyrosine kinase inhibitor (TKI) targeting Philadelphia chromosome-positive leukemia, plays an important role in cancer treatment. It achieves therapeutic purposes by inhibiting specific kinase activity to slow down the growth and division of cancer cells. For many patients who need this treatment, whether dasatinib is covered by medical insurance reimbursement is a matter of great concern.

After inquiries and understanding, dasatinib has been included in the scope of medical insurance reimbursement in some areas. This means that patients who meet the medical insurance policy can enjoy a certain degree of cost reduction when purchasing the drug. This undoubtedly brings good news to patients who need long-term treatment with dasatinib and greatly reduces their financial burden. However, medical insurance reimbursement policies vary by region. Medical insurance departments in different regions may formulate different reimbursement policies and standards based on local actual conditions and the affordability of medical insurance funds. Therefore, before purchasing dasatinib, patients should consult their local medical insurance department or hospital pharmacy to learn about specific reimbursement policies and related information.
In addition, even if dasatinib has been included in the scope of medical insurance reimbursement, patients still need to pay attention to some details. For example, you need to ensure that the dasatinib you purchase complies with the provisions of the medical insurance policy, you need to purchase the drug at a designated medical institution, and keep the relevant drug purchase vouchers, etc. Only in this way can patients successfully enjoy the benefits brought by medical insurance reimbursement.
In short, the original drug of dasatinib has been included in the scope of medical insurance reimbursement in some regions, and the price of each box may be around 10,000 yuan, but the specific policies vary from region to region. Patients need to understand local medical insurance policies and follow relevant regulations to ensure they enjoy the reimbursement they deserve.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)